Cancer Cell Biology

癌细胞生物学

• 批准号: 7944540
• 负责人: M. LUISA IRUELA-ARISPE
• 金额: $ 5.59万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-02 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944540
• 关键词: Achievement; Animal Model; Area; Basic Science; Biological; Biological Models; Biological Sciences; Biology; Biomedical Research; Biomedical Technology; California; Cancer Biology; Cancer Center Support Grant; Cancer Detection; Cells; Cellular biology; Chemistry; Chin; Clinical; Collaborations; Communities; Complement; Comprehensive Cancer Center; Consultations; Core Facility; Critiques; Derivation procedure; Detection; Development; Developmental Biology; Developmental Cell Biology; Developmental Process; Drosophila genus; Drug Delivery Systems; Educational workshop; Emerging Technologies; Engineering; Faculty; Failure; Focus Groups; Fostering; Funding; Genetic; Genetic Screening; Gifts; Goals; Grant; Hemangioma; Hospitals; Housing; Information Dissemination; Institutes; Interest Group; Investments; Joint Ventures; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Knowledge; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of prostate; Mammary Neoplasms; Modeling; Molecular; Monitor; Mutation; Names; Nanotechnology; National Cancer Institute; Paper; Participant; Pathologist; Pathway interactions; Peer Review; Positioning Attribute; Preventive; Publications; Publishing; Reagent; Recruitment Activity; Refractory; Reporting; Research; Research Infrastructure; Research Personnel; Resource Sharing; Rome; Science; Scientist; Screening procedure; Seeds; Series; Signal Transduction; Stem Cell Research; Stem cells; Strategic Planning; Subgroup; The Sun; Therapeutic; Therapeutic Studies; Translations; Tumorigenicity; Universities; Ursidae Family; Work; Zebrafish; anticancer research; base; cancer cell; cancer stem cell; cancer therapy; cost; frontier; human disease; improved; innovation; insight; interest; member; metaplastic cell transformation; mouse model; nanobiology; nanosystems; neoplastic cell; outcome forecast; paracrine; pre-clinical; prognostic; programs; response; stem; stem cell biology; symposium; tumor; tumor growth; tumor progression

The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the "Molecular, Cellular and Developmental Biology (MCDB) Program Area." In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies; (2) identify appropriate leaders and members for these focus areas; (3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas; and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology; the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy; (2) cancer stem cell identification and eradication; and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

CCB项目领域有24个核心成员，分布在这三个重点领域。在电流期间